Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 7.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,370 shares of the company’s stock after acquiring an additional 1,380 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Henry Schein were worth $1,224,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently bought and sold shares of the company. World Asset Management Inc increased its holdings in Henry Schein by 10.5% in the first quarter. World Asset Management Inc now owns 10,609 shares of the company’s stock valued at $638,000 after buying an additional 1,010 shares during the last quarter. Bank of Montreal Can boosted its stake in Henry Schein by 1.8% in the first quarter. Bank of Montreal Can now owns 504,345 shares of the company’s stock valued at $30,318,000 after acquiring an additional 9,030 shares in the last quarter. Gs Investments Inc. boosted its stake in Henry Schein by 3.3% in the first quarter. Gs Investments Inc. now owns 9,569 shares of the company’s stock valued at $575,000 after acquiring an additional 305 shares in the last quarter. K.J. Harrison & Partners Inc acquired a new position in Henry Schein in the first quarter valued at $1,202,000. Finally, Coastline Trust Co boosted its stake in Henry Schein by 19.0% in the first quarter. Coastline Trust Co now owns 30,040 shares of the company’s stock valued at $1,806,000 after acquiring an additional 4,790 shares in the last quarter.
Shares of HSIC opened at $66.71 on Wednesday. Henry Schein, Inc. has a fifty-two week low of $56.58 and a fifty-two week high of $91.35. The stock has a market cap of $9.45 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.89. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.30 and a quick ratio of 0.68.
Several equities analysts have issued reports on the stock. Robert W. Baird restated a “neutral” rating on shares of Henry Schein in a research note on Monday, March 25th. Zacks Investment Research upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, May 2nd. BidaskClub downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Tuesday. Cleveland Research restated a “hold” rating on shares of Henry Schein in a research note on Thursday, May 2nd. Finally, Barclays decreased their price objective on shares of Henry Schein from $73.00 to $63.00 and set an “equal weight” rating for the company in a research note on Thursday, February 21st. Six research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $77.57.
In related news, Director Philip A. Laskawy sold 1,084 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $59.86, for a total value of $64,888.24. Following the completion of the sale, the director now owns 32,899 shares in the company, valued at $1,969,334.14. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.06% of the stock is owned by company insiders.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: What is total return in investing?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.